Literature DB >> 1702767

Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment.

L Nencioni1, G Volpini, S Peppoloni, M Bugnoli, T De Magistris, I Marsili, R Rappuoli.   

Abstract

Formaldehyde treatment is a method routinely used to detoxify diphtheria, tetanus, and pertussis toxins as well as other molecules suitable for vaccine production. To investigate whether chemical detoxification alters the immunological properties of vaccine components, we have treated the pertussis toxin mutant PT-9K/129G with formaldehyde and tested the properties of the resulting molecules. Very low concentrations of formaldehyde stabilize the molecule without affecting the physicochemical and immunological parameters. Increasing doses of formaldehyde abolish the mitogenic and hemagglutinating activities of PT-9K/129G. At the same time, the molecule loses the ability to be recognized by a monoclonal antibody specific for a major protective epitope on the S1 subunit of pertussis toxin and its affinity for anti-pertussis toxin polyclonal antibodies is also reduced. In marked contrast, the ability of PT-9K/129G to be recognized by human T-cell clones is not affected by Formalin treatment. In vivo, the formaldehyde-treated molecules induce amounts of specific antibodies comparable with those of untreated molecules but significantly lower levels of toxin-neutralizing antibodies. Furthermore, the formaldehyde-treated molecules also show a reduced protective activity in the intracerebral challenge assay.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702767      PMCID: PMC257803          DOI: 10.1128/iai.59.2.625-630.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Determination of antigen-specific immunoglobulin content in ascitic fluids and antisera.

Authors:  M Mariani; D Nucci; L Bracci; P Neri; G Antoni
Journal:  J Immunol Methods       Date:  1986-09-27       Impact factor: 2.303

2.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.

Authors:  L Nencioni; M Pizza; M Bugnoli; T De Magistris; A Di Tommaso; F Giovannoni; R Manetti; I Marsili; G Matteucci; D Nucci
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

3.  Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.

Authors:  A Kimura; K T Mountzouros; P A Schad; W Cieplak; J L Cowell
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Separation and purification of the hemagglutinins from Bordetella pertussis.

Authors:  Y Sato; J L Cowell; H Sato; D G Burstyn; C R Manclark
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

5.  The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells.

Authors:  P Gillenius; E Jäätmaa; P Askelöf; M Granström; M Tiru
Journal:  J Biol Stand       Date:  1985-01

6.  Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.

Authors:  J Storsaeter; P Olin; B Renemar; T Lagergård; R Norberg; V Romanus; M Tiru
Journal:  Pediatr Infect Dis J       Date:  1988-09       Impact factor: 2.129

7.  Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide.

Authors:  R D Sekura; Y L Zhang; R Roberson; B Acton; B Trollfors; N Tolson; J Shiloach; D Bryla; J Muir-Nash; D Koeller
Journal:  J Pediatr       Date:  1988-11       Impact factor: 4.406

8.  Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map.

Authors:  M T De Magistris; M Romano; A Bartoloni; R Rappuoli; A Tagliabue
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

9.  Dissecting human T cell responses against Bordetella species.

Authors:  M T De Magistris; M Romano; S Nuti; R Rappuoli; A Tagliabue
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.

Authors:  A Podda; L Nencioni; M T De Magistris; A Di Tommaso; P Bossù; S Nuti; P Pileri; S Peppoloni; M Bugnoli; P Ruggiero
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  23 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

2.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

3.  Confocal microscopy study of pertussis toxin and toxoids on CHO-cells.

Authors:  Yajun Tan; Roland A Fleck; Catpagavalli Asokanathan; Chun-Ting Yuen; Dorothy Xing; Shumin Zhang; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 4.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 5.  The family of bacterial ADP-ribosylating exotoxins.

Authors:  K M Krueger; J T Barbieri
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

Review 6.  Formaldehyde crosslinking: a tool for the study of chromatin complexes.

Authors:  Elizabeth A Hoffman; Brian L Frey; Lloyd M Smith; David T Auble
Journal:  J Biol Chem       Date:  2015-09-09       Impact factor: 5.157

7.  Characterization of new formalin-detoxified botulinum neurotoxin toxoids.

Authors:  James E Keller
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

8.  Identification of B-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  P H Ibsen; A Holm; J W Petersen; C E Olsen; I Heron
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

9.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7.

Authors:  Jamie N Sutherland; Jennifer A Maynard
Journal:  Biochemistry       Date:  2009-12-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.